Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
Genomic and Drug Response Profiling of Fatal TCF3-HLF-Positive Pediatric Acute Lymphoblastic Leukaemia Identifies Recurrent Mutation Patterns and Novel Therapeutic OptionsJean‐Pierre Bourquin, Björn Stade, Thomas S. Risch et al.|Unknown|2015Cited by 0